Couples undergoing infertility treatments are more aware than ever of preimplantation genetic screening and diagnosis, yet patients and practitioners alike are still struggling with understanding the technologies being used, their capabilities and limitations, and their clinical, legal, and ethical implications. Cambridge Healthtech Institute’s Third Annual Reproductive Genetic Diagnostics conference aims to highlight a number of technologies and their differences, as well as how effective they are at uncovering a variety of genetic abnormalities. Considerations for mosaic embryos, biopsy techniques, and genetic counseling will also be discussed. Special attention will be paid to expanded carrier screening, its role in the direct-to-consumer market, and the potential for other molecular tests for infertility and implantation failure. Future directions for the role of gene editing and non-invasive embryo diagnostics will also be discussed.